Dr. Ronghao Li, President
Dr. Li is well-known for his contributionindeveloping serum-free cell culture methods for many different types of mammalian cells. He has become an expert in mammalian process development for recombinant protein manufacturing including therapeutic monoclonal antibodies and other type of protein molecules when working in Genentech’s process development department. After his career in Genentech he has worked for several other companies for drug discovery research and product development.Most recently he severed as VP atHengruiPharmaceticalsto lead the effort for large molecule drug discovery before founding Zhuhai Kairui Biotech.
Mr. John Wu,CEO
Mr. Wu has been working for Pfizer and Amgen for many years before joining Drs. Li and Mather to found Zhuhai Kairui Biotech. He has a Master of Science degree in pharmacology and served as pharmacologist in many drugs discovery projects. During his research he has accumulated intense experience in cell culture techniques and their applications in both small and large molecule drug discovery. He is also experienced in applications of other technologies such as metabonomic and transcriptional regulations in drug discovery research.
Dr. Jennie Mather, Chief Scientific Advisor
Dr. Mather was one of the pioneers in serum-free cell culture technologies. She had worked with Dr. Gordon Sato in UCSD late 1970s to develop serum-free culture techniques for biomedical research, and soon became the leading expert of this field. She has published the world’s first serum-free cell culture methodology book and gave the first serum-free cell culture laboratory workshop training in Cold Spring Harbor Laboratory, both in early 1980s after she became a faculty member of Rockefeller University. In 1984 Dr. Mather joined Genentech and applied her serum-free culture skills to help develop manufacturing process of Genentech’s first 10 recombinant protein drugs. Before Joining Dr. Li and Mr. Wu to found Zhuhai Kairui, Dr. Mather founded Raven Biotechnologies, Inc. which was later acquired by MacroGenics in 2008.